Another limitation was the small sample size of patients with cT2-T3bN0-2M0 tumors included in our study; we will embark on a prospective, case-control multicenter study, including evaluating the efficacy of the combination therapy in specific subgroups based on HER2 expression levels, to further validate our findings and provide new approaches to guide neoadjuvant therapy or bladder-sparing treatment for bladder cancer. This evidence concerns the gene ERBB2 and urinary bladder cancer.